|Bid||21.72 x 1800|
|Ask||21.73 x 1400|
|Day's range||21.50 - 21.80|
|52-week range||16.63 - 32.23|
|Beta (5Y monthly)||1.73|
|PE ratio (TTM)||240.56|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||25 Jun 2007|
|1y target est||N/A|
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 14, 2020 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (NasdaqGS: MYL), if they purchased the Company’s securities between May 9, 2018 and May 6, 2019, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Pennsylvania.
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
Shareholder rights law firm Robbins LLP announces that a purchaser of Mylan N.V. (NYSE: MYL) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between May 9, 2018 and May 6, 2019. Mylan develops and manufactures over-the-counter pharmaceutical products.
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between May 9, 2018 and May 6, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Mylan investors under the federal securities laws.
Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V. and Upjohn Inc., which is expected to occur in mid-2020. The Viatris board will oversee a company with a combined global presence and a mission to serve the health needs of people around the world.
Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide. “The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced.